Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
15 October 2018 |
Main ID: |
EUCTR2015-003026-14-SI |
Date of registration:
|
14/03/2016 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS TO ORAL DELAFLOXACIN IN ADULT SUBJECTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA
|
Scientific title:
|
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS TO ORAL DELAFLOXACIN IN ADULT SUBJECTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA |
Date of first enrolment:
|
18/03/2016 |
Target sample size:
|
860 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-003026-14 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: yes Other trial design description: I.V. to oral switch If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: yes Other specify the comparator: Matching Placebo to Dela oral, Moxi oral and Moxi i.v. Number of treatment arms in the trial: 2
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Argentina
|
Brazil
|
Bulgaria
|
Colombia
|
Georgia
|
Germany
|
Greece
|
Hungary
|
Latvia
|
Poland
|
Romania
|
Russian Federation
|
Serbia
|
Slovenia
|
South Africa
|
Spain
|
Ukraine
|
United States
| | | | | | |
Contacts
|
Name:
|
Melinta Clinical Trials
|
Address:
|
300 Tri-State International, Suite 272
IL 60069
Lincolnshire
United States |
Telephone:
|
+1312724 9400 |
Email:
|
clinicaltrials@melinta.com |
Affiliation:
|
Melinta Therapeutics, Inc. |
|
Name:
|
Melinta Clinical Trials
|
Address:
|
300 Tri-State International, Suite 272
IL 60069
Lincolnshire
United States |
Telephone:
|
+1312724 9400 |
Email:
|
clinicaltrials@melinta.com |
Affiliation:
|
Melinta Therapeutics, Inc. |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Male or female 18 years of age or older
2. Evidence of acute onset of CABP with 2 or more of the following symptoms (new or worsening)
• Cough
• Production of purulent sputum consistent with bacterial infection
• Difficulty breathing
• Chest pain due to pneumonia
AND have at least 2 of the following findings:
• Fever (oral temperature >38.0°C)
• Hypothermia (oral temperature <35.0°C)
• Tachycardia (heart rate >100 beats/min)
• Tachypnea (respiratory rate >18 breaths/min)
AND have at least 1 of the following findings:
• Hypoxemia (oxygen saturation < 90% or PaO2 < 60 mmHg on room air or with subject’s baseline [pre-CABP under study] supplemental oxygen
• Clinical evidence of pulmonary consolidation and/or presence of pulmonary rales
• An elevated white blood cell count (WBC) > 10,000/mm3 or 15% immature neutrophils (bands), regardless of total peripheral WBC count or leukopenia with WBC < 4500/mm3
3. Presence of lobar, multilobar, or patchy parenchymal infiltrate(s) consistent with acute bacterial pneumonia on a pulmonary imaging study within 48 hours before the first dose of study drug
4. PORT risk class of II to V
5. Must be a suitable candidate for possible IV to oral switch antibiotic therapy and must also be able to swallow large tablets/capsules intact without crushing
Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 559 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 301
Exclusion criteria: 1. A medical history of significant hypersensitivity or allergic reaction to antibiotics of the quinolone or oxazolidinone class or study drug excipients according to the investigator
2. Any infection expected to require other systemic antibiotics in addition to study drug
3. Receipt of systemic antibiotic therapy in the 7 days before enrollment
• one dose of a single potentially effective, short-acting antibacterial drug or drug regimen for CABP within 24 hours before enrollment is allowed - limited to 25% of enrolled patients
4. Respiratory infection confirmed or suspected to be secondary to hospital-required or ventilator-associated pneumonia or requires treatment in an intensive care setting, or mechanical ventilation
5. Current or suspected diagnosis of viral, fungal, or aspiration pneumonia, noninfectious causes of pulmonary infiltrates, lung cancer, cystic fibrosis, tuberculosis, empyema (not including sterile parapneumonic effusions)
6. Known anatomical or pathological obstruction or history of bronchiectasis or GOLD Stage 4 COPD or history of post obstructive pneumonia
7. Severely compromised immune system
8. Other exclusions include those described in the safety label for drugs in the quinolone and /or oxazolidinone classes such as QT prolongation, proarrhythmic conditions, concomitant use of drugs known to cause QT prolongation, peripheral neuropathy, tendon disorders, history of myasthenia gravis, liver disease, severe renal disease, seizures and concomitant use of MAO A or B inhibitor agents and adrenergic serotonergic agents
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Community-Acquired Bacterial Pneumonia MedDRA version: 20.1
Level: LLT
Classification code 10010120
Term: Community acquired pneumonia
System Organ Class: 100000004862
|
Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
|
Intervention(s)
|
Product Name: Delafloxacin Product Code: RX-3341-83 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: Delafloxacin meglumine CAS Number: 352458-37-8 Current Sponsor code: RX-3341-83 Other descriptive name: DELAFLOXACIN MEGLUMINE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300-
Product Name: Delafloxacin oral tablet Product Code: RX-3341-83 Pharmaceutical Form: Tablet INN or Proposed INN: Delafloxacin meglumine CAS Number: 352458-37-8 Current Sponsor code: RX-3341-83 Other descriptive name: DELAFLOXACIN MEGLUMINE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 450- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use
Product Name: Moxifloxacin Pharmaceutical Form: Solution for infusion INN or Proposed INN: Moxifloxacin CAS Number: 186826-86-8 Other descriptive name: MOXIFLOXACIN HYDROCHLORIDE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1.6- Pharmaceutical form of the placebo: Solution for injection/infusion Route of administration of the placebo: Intravenous use
Product Name: Moxifloxacin Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Moxifloxacin CAS Number: 186826-86-8 Other descriptive name: MOXIFLOXACIN HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use
Product Name: Linezolid Pharmaceutical Form: Solution for infusion INN or Proposed INN: Linezolid CAS Number: 165800-03-3 Other descriptive name: LINEZOLID Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Solution for injection/infusion Route of administration of the placebo: Intravenous use
|
Primary Outcome(s)
|
Secondary Objective: EMA - To assess the clinical efficacy of IV to oral delafloxacin in adult subjects with CABP based on ECR defined as improvement at 96 hours (± 24 hours) after the first dose of study drug compared to IV to oral moxifloxacin in the ModITT and ModCE populations. - To assess the clinical efficacy of IV to oral delafloxacin in adult subjects with CABP at the TOC visit compared to IV to oral moxifloxacin in the Modified MITT (ModMITT) and Modified ME (ModME) populations. - To assess the microbiologic response to delafloxacin in respiratory pathogens in the ModMITT and ModME populations. - To assess the safety and tolerability of IV to oral delafloxacin in adult subjects with CABP in safety population. - To assess the all-cause mortality in adult subjects with CABP on Day 28 in ModITT. - To assess delafloxacin PK in adult subjects with CABP in PK population. FDA Secondary objectives for FDA can be found at pages 34-35 of the current protocol amendment.
|
Primary end point(s): The Clinical Outcome responder rate at 5 to 10 days after the last dose of study drug (TOC) defined as resolution or near resolution of the symptoms of CABP present at study entry, and no use of additional antimicrobial therapy for the current infection, and no new symptoms associated with the current CABP infection (success) in the ModITT and ModCE populations.
|
Main Objective: EMA To assess the clinical efficacy of IV to oral delafloxacin in adult subjects with CABP at 5 to 10 days after the last dose of study drug (TOC) compared to IV to oral comparator study drug arm in the Modified ITT (ModITT) and Modified CE (ModCE) populations. FDA To assess the clinical efficacy of IV to oral delafloxacin in adult subjects with CABP based on Early Clinical Response (ECR) defined as improvement at 96 hours (± 24 hours) after the first dose of study drug compared to IV to oral moxifloxacin in the ITT population.
|
Timepoint(s) of evaluation of this end point: Days 5 to 10
|
Secondary Outcome(s)
|
Secondary end point(s): The secondary efficacy endpoints are:
- ECR defined as improvement at 96 hours (± 24 hours) after first dose
of study drug in at least 2 of the following symptoms: chest pain,
frequency or severity of cough, amount and quality of productive sputum
and difficulty breathing and no worsening of any of the other symptoms
in the ModITT and ModCE populations
- ECR with the addition of improvement in vital signs and no worsening
of the 4 symptoms required as Response in the ModITT and ModCE
populations
- Clinical Outcome at EOT (ModITT and ModCE)
- Clinical Outcome at TOC in the ModMITT and ModME populations
- Microbiologic response (ModMITT and ModME)
- All-cause mortality (ModITT)
|
Timepoint(s) of evaluation of this end point: Clinical Outcome at the Test of Cure (TOC) visit, 5 to 10 days after the last dose of study drug
All-cause mortality (ModITT)- Day 28
96 h ± 24 h for Early Clinical Response
|
Secondary ID(s)
|
NCT02679573
|
ML-3341-306
|
2015-003026-14-HU
|
Source(s) of Monetary Support
|
Melinta Therapeutics, Inc.
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|